SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American ...

– Results from Phase 2b ReNeu trial of mirdametinib in NF1-PN accepted for oral presentation –

Related Keywords

United States ,Philadelphia ,Pennsylvania ,American ,Bruno Vincenzi ,Jim Cassidy ,Bernd Kasper ,Samantha Hilson Sandler ,Christopher Moertel ,Health Supervision For Children With Neurofibromatosis Type ,Prada ,Desmoid Tumor Working Group ,European Medicines Agency ,Drug Administration ,Us Department Of Commerce ,Springworks Therapeutics Inc ,Linkedin ,Children Tumor Foundation ,Youtube ,Twitter ,American Society Of Clinical Oncology ,Nasdaq ,European Commission ,Works Therapeutics ,Clinical Oncology ,Annual Meeting ,New Drug Application ,Chief Medical Officer ,Rapid Oral ,Developmental Therapeutics ,Molecularly Targeted Agents ,Orphan Drug ,Fast Track ,Rare Pediatric Disease ,Response Evaluation Criteria ,Solid Tumors ,Melanoma Skin Cancers ,Private Securities Litigation Reform Act ,Springwork Annual Report ,Orphanetj Rare ,Adults With ,Related Plexiform ,Children With Neurofibromatosis Type ,Dei Tos ,Soft Tissue Tumours ,Tumor Working ,Report Series ,Rare Diseases ,Region ,